Empowered Funds
ALLO icon

Empowered Funds’s Allogene Therapeutics ALLO Stock Holding History

Empowered Funds’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$197K Buy
+122,895
New +$234K ﹤0.01% 2266

Other funds holding ALLO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Empowered Funds's ALLO Position: Q3 2026 in Review

Empowered Funds opened a new position in Allogene Therapeutics (ALLO) in Q3 2026: 122,895 shares worth $197K. The stake represents ﹤0.01% of the portfolio and ranks #2266 among its holdings.

141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Empowered Funds held 122,895 shares of Allogene Therapeutics worth $197K as of Q3 2026.
  • Allogene Therapeutics was a new Empowered Funds position in Q3 2026.
  • Allogene Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2266 holding.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.